Intralase refined in the UK

Article

Optimax has refined its Intralase technology to introduce what it calls 'unprecedented' levels of control for its surgeons through the rollout of the new generation iFS IntraLase Lasers across its UK clinics.

Optimax has refined its Intralase technology to introduce what it calls 'unprecedented' levels of control for its surgeons through the rollout of the new generation iFS IntraLase Lasers across its UK clinics.

The laser engine runs almost 3 times faster meaning the cornea is exposed for the shortest possible period. Optimax claims that further technical refinements mean that complications which can lead to halos, glare and potential night vision problems are virtually eliminated.

“This is a great technical step forward for Optimax, meaning better vision outcomes than ever before. It shows our commitment to reviewing and updating our technology, offering laser eye surgery patients the most advanced procedures currently available,” said medical director Malcolm Samuel.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.